口服雷帕霉素治疗结节性硬化症患者肾血管平滑肌脂肪瘤的疗效观察
Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease.
作者信息
Torun Dilek, Micozkadioglu Hasan, Gedikoglu Murat, Ozelsancak Ruya, Tekkarismaz Nihan
机构信息
Department of Nephrology, Adana Dr. Turgut Noyan Research and Medical Center, Faculty of Medicine, Baskent University, Adana, Turkey.
Department of Interventional Radiology, Adana Dr. Turgut Noyan Research and Medical Center, Faculty of Medicine, Baskent University, Adana, Turkey.
出版信息
Saudi J Kidney Dis Transpl. 2019 Mar-Apr;30(2):545-548. doi: 10.4103/1319-2442.256866.
We present a case of a 32-year-old female who had been diagnosed tuberous sclerosis complex (TSC) two years ago. In view of serious hemorrhagic complication risk of the selective embolization, we commenced her on oral rapamycin therapy for regression of angiomyolipomas (AMLs). On the 1 year of rapamycin treatment, bilateral renal AMLs were regressed and bilateral selective embolization of the AML was performed after the 1 year of treatment. Rapamycin therapy may regress renal lesions in TSC disease. Therefore, it may increase surgical intervention.
我们报告一例32岁女性，她于两年前被诊断为结节性硬化症（TSC）。鉴于选择性栓塞存在严重出血并发症风险，我们开始让她口服雷帕霉素治疗，以促使肾血管平滑肌脂肪瘤（AML）消退。在雷帕霉素治疗1年后，双侧肾AML消退，治疗1年后对AML进行了双侧选择性栓塞。雷帕霉素治疗可能使TSC疾病中的肾脏病变消退。因此，它可能增加手术干预。
Zotero 插件